Class 10 - Neurotransmitters

Neurotransmitters

  • Where we left off

    • Chemical transmission involves packaging NTs into SVs

      • The transporter present on SV determines what can be packaged

    • Synaptic vesicle release is 

      • Ca2+-dependent

      • is regulated

    • SV are recovered and refilled

      • Termed synaptic vesicle cycle

  • Synaptic vesicle recycling 

    • molecular mechanisms regulate synaptic transmission which are critical for function

      • Need to be able to respond to sustained signals

    • To support rapid and repeated rounds of release, synaptic vesicles undergo a trafficking cycle

      • Will study this in detail in next Unit

      • We do not make a new SV everytime from the soma 

  • Neurotransmitters

    • Are chemical transducers

      • Signal that one neuron gives to another 

    • released by electrical impulse into the synaptic cleft from presynaptic membrane from synaptic vesicles

    • they then diffuse to the postsynaptic membrane 

    • react and activate the receptors present leading to initiation of new electrical signals.

  • Properties of neurotransmitters

    • Synthesized in the presynaptic neuron

    • Localized to vesicles in the presynaptic neuron

    • Released from the presynaptic neuron under physiological conditions

    • Rapidly removed from the synaptic cleft by uptake or degradation

    • Presence of receptor on the post-synaptic neuron

    • Binding to the receptor elicits a biological response

  • Neurotransmitter criteria

    • A CLASSICAL NEUROTRANSMITTER

  • Fate of neurotransmitters

    • consumed (broken down or used up) at postsynaptic membrane leading to action potential generation.

    • Degraded by enzymes present in synaptic cleft.

      • NMJ

    • Reuptake mechanism (reutilization) 

      • this is the most common fate.

  • Chemical Classification of neurotransmitters

    • Can also be classified into categories based on size 

      • 1. Small molecule transmitters (Classical)

        • Ester

        • Amines

        • Amino acids

      • 2. Neuroactive peptides

      • 3. Gaseous neurotransmitters

      • 4. ATP

      • 5. Endocannabinoids

    • Peptides = non classical neurotransmitters 

    • Other 

      • Gas neurotransmitters

      • ATP

      • Endocannabinoids 

    • Gases and endocannabinoids cannot be packed into SV because they can diffuse 

      • But they elicit change in another neuron and have receptors 

  • Classical Neurotransmitters

    • small molecule transmitters

    • synthesized in cytoplasm from compounds of intermediary metabolism

      • Ester (Acetylcholine)

      • Biogenic Amines (dopamine, norepinephrine, epinephrine, serotonin, histamine)

      • Amino Acids (gamma-amino butyric acid = GABA, glycine, glutamate)

  • Neuroactive Peptides

    • synthesized on rough ER and processed for secretion by the Golgi apparatus

      • 1. Hypothalamic-releasing Hormones

      • 2. Neurohypophyseal Hormones 

        • Vasopressin, oxytocin

      • 3. Adenohypophyseal Hormones  

        • Growth hormone, endorphins, melanocyte-stimulating hormone

      • 4. Gastrointestinal Peptides 

        • Gastrin, substance P, insulin, glucagon, vasoactive intestinal peptide

      • 5. Others

        • angiotensin, bradykinin, sleep peptides

    • Debatable whether these are neurotransmitters or a class by themselves: hormones

    • do not fit all the criteria of neurotransmitters

    • their actions are far-reaching, rather than just synaptic

  • Atypical Neurotransmitters

    • In addition to the conventional neurotransmitters, some unusual molecules are used for signaling between neurons and their targets.

    • can be considered as neurotransmitters because of their roles in interneuronal signaling and because their release from neurons is regulated by Ca2+.

    • are unconventional in comparison with typical neurotransmitters because 

      • they are not stored in synaptic vesicles 

      • not released from presynaptic terminals via exocytotic mechanisms.

    • are often associated with retrograde signaling 

      • i.e. from postsynaptic cells back to presynaptic terminals

      • (back to the soma)

    • Include gaseous transmitters and endocannabinoids and ATP

  • ATP

    • Virtually most, and possibly all, types of secretory vesicles found in cells contain ATP, which often accumulates at high concentrations and, commonly, in conjunction with different types of neurotransmitters.

    • Thus synaptic vesicles released by the terminal membrane of a nerve contain ATP as well as other neurotransmitters

    • BUT ATP can only function as a neurotransmitter if the post-synaptic terminal membrane contains ATP receptors (purigenic receptors)

    • Activity-dependent release of ATP from synapses, axons and glia activates purinergic membrane receptors that modulate intracellular calcium and cyclic AMP.

    • ATP is now recognized as a co-transmitter in all nerves in the peripheral and central nervous systems.

    • In addition to vesicular release there are also non-vesicular mechanisms for ATP release from neurons which are likely to have a broader range of functions than synaptic release

      • Voltage- and Ca2+ o-gated CALHM channels constitute a novel ion channel family

      • Voltage gated Calhm1/3 channels can release ATP I taste receptor cells

    • Receptor…P2X receptor 

  • Gaseous transmitters

    • NO and CO are small gaseous molecules that can be synthesized de novo in neuronal tissue and can diffuse readily through the plasma membrane.

    • Not characterized as neurotransmitters until the 1980s

    • Biosynthetic enzymes localized to specific neuronal populations and inhibitors of the enzyme block neurotransmission in certain systems

    • Somewhat controversial  as they cannot be stored in synaptic vesicles, released by exocytosis, or act at receptor proteins on cell membranes

  • Endocannabinoids 

    • a family of related endogenous signals that interact with cannabinoid receptors

      • anandamide and 2-arachidonoylglycerol (2-AG) have best evidence

    • At least two types of cannabinoid receptors have been identified

      • CB1 and CB2

      • GPCRs

      • most actions of endocannabinoids in the CNS mediated by the CB1 type

    • participate in several forms of synaptic regulation. 

      • best evidence so far is inhibition of communication between presynaptic inputs and their postsynaptic target cells.

    • Can have neurotransmitters we consider released on the postsynaptic cells and signaling back to the presynaptic terminal 

  • Original Dale’s Law (1950s)

    • “A mature neuron makes use of the same transmitter substance at all of its synapses”

    • Discovery of peptide transmitters led to modification

    • Modified Dale’s Law = “A mature neuron makes use of the same combination of chemical transmitters at all of its synapses.”

      • when co- secretion occurs, it usually involves a small molecule transmitter and one or more peptides

  • SVs vs DCVs

    • Small, clear synaptic vesicles (SVs) generally contain low–molecular weight neurotransmitters, whereas neuropeptides are packaged in larger, dense-core vesicles (DCVs)

      • Can regulate their endocytosis differently 

    • Packaging different classes of molecules into SVs and DCVs provides for an effective means of regulating their exocytosis independently

    • DCVs often contain multiple neuropeptides, which are released together during DCV exocytosis

  • Small molecule transmitter: Synthesis, transport, and release 

    • 1. Enzymes for synthesis made in rER

    • 2. Transported to Golgi

    • 3. Modified in Golgi (e.g. glycosylated)

    • 4. Transported down axons

      • Soluble enzymes – slow anterograde axonal transport

      • Other enzymes – fast axonal transport

    • 5. Precursors taken up by transporters and used by enzymes to synthesize transmitter in terminal

    • 6. Synthesized neurotransmitter loaded into vesicles by vesicular transport proteins

      • Typically into clear-core vesicles (synaptic vesicles)

      • Exceptions: biogenic amines often in both SVs and DCVs

        • Serotonin and norepinephrine in dense-core vesicles

    • 7. Stimulus results in their release

      • Released transmitter is deactivated by enzymes or re-uptake

  • Neuropeptide transmitters:  Synthesis, transport, and release 

    • 1. Polypeptides (pre-propeptides: larger than final peptide) are synthesized in rER and converted into a pro-peptide. Enzymes for cleavage are also synthesized in rER

    • 2. Both transported to Golgi and packaged into vesicles

    • 3. Pro-peptide and enzyme filled vesicles moved down axons by fast axonal transport

    • 4. Enzymes cleave propeptide to produce peptide neurotransmitter

      • Remains in dense-core vesicle

    • 5. Released into synaptic cleft by exocytosis

    • 6. After release, peptide neurotransmitters diffuse away and are degraded by proteolytic enzymes

      • No reuptake like small-molecule neurotransmitters

    • A number of different receptors 

    • Agnost

      • Binds to a receptor and elicits the same response as a ligand 

    • Antagonist 

      • Binds to receptor and prevents response 

  • Seven processes in neurotransmitter action

      • Anything not packaged quickly gets destroyed by enzymes 

      • Packaged into vesicles protects neurotransmitters from enzymes 










  • Drugs 

  • Neurotransmitters found in the nervous system  


* metabotropic receptors are modulatory 

The neurotransmitter when it binds to the receptor signals

Early in development GABA is excitatory

  • Ester: Acetylcholine (ACh)

    • The first transmitter to be discovered.

      • First identified by Henry Dale (1915) and confirmed as a neurotransmitter by Otto Loewi, 1921

    • The primary neurotransmitter secreted by the efferent axons (motor neurons) of the central nervous system.

    • All muscular movement is accomplished by the release of acetylcholine.

    • Appears to be involved in regulating voluntary movement, REM sleep, perceptual learning, and memory.

    • Too much acetylcholine is associated with depression, and too little in the hippocampus has been associated with dementia

  • ACh synthesis 

    • In the cholinergic neurons acetylcholine is synthesized from choline.  

      • Choline is a water-soluble essential nutrient (get it from our diet)

      • Dietary source

    • This reaction is activated by choline acetyltransferase (ChAT) 

      • In CNS

  • ACh removal 

    • acetylcholinesterase (AChE) is a serine protease that hydrolyzes the neurotransmitter acetylcholine.

    • ↑ [AChE] present in synaptic cleft

    • AChE synthesized in rER in soma and major dendrites and transported to presynaptic terminal

    • Hydrolyses ACh in the synaptic cleft

      • Liberated choline is taken back up by terminal and reused for synthesis of ACh

  • Very few places where we actually make ACh in the CNS…but a lot of projections of cholinergic neurons 



  • ACh Neuropharmacology 

    • Disesases ACh implicated in 

      • Myasthenia Gravis 

        • an autoimmune disease which results in muscle fatigability and weakness throughout the day.

        • Antibodies attack acetylcholine (ACh) receptors at the post-synaptic neuromuscular junction (NMJ)

        • cause ACh receptor blockade

      • Alzheimer's

        • ACh+ neurons in nucleus of Meynert degenerated

      • Sleep disorders

        • ACh is involved in controlling REM sleep as well as arousal

        • In patients with decreased ACh (like aging and Alzheimer's) REM sleep, total sleep time, and delta sleep are decreased

    • Drugs and toxins that influence ACh

      • Donepezil (Aricept)

        • AChE inhibitor

        • Used for mild to moderate patients

      • Botulinum toxin

        • An Ach antagonist

        • prevents release by terminal buttons.

      • Black widow spider venom

        • triggers the release of ACh.

      • Neostigmine

        • inhibits AChE 

        • Used to improve muscle tone in people with myasthenia gravis

      • Hemicholinium

        • A drug that inhibits the uptake of choline.

        • has no clinical use

  • Glutamate

    • The carboxylate anions and salts of glutamic acid are known as glutamate

    • Is a non-essential amino acid

      • Does not cross BBB

      • Must be synthesized locally

      • We have to make it…cannot get it from diet 

    • is the most abundant excitatory neurotransmitter in the vertebrate nervous system.

      • Nearly all excitatory synapses in CNS are glutamtergic

      • Over ½ of all synapses release glutamate

    • Elevated concentrations are toxic

      • Often occurs after injury

      • Have to regulate the release 

    • Does have some other functions

      • Synthesis of proteins and peptides

    • Important  for Learning and memory

  • Glutamate synthesis

    • a nonessential amino acid that does not cross the blood-brain barrier and must be synthesized in neurons from local precursors

    • Synthesized in CNS by 2 processes

      • 1. Synthesized from glutamate recycled from synaptic cleft (see diagram)

        • the most prevalent glutamate precursor in synaptic terminals is glutamine

      • 2. some of the glucose metabolized by neurons can also be used for glutamate synthesis.

        • Glucose enters neuron by facilitated diffusion and is metabolized 

        • synthesized by transamination of 2-oxoglutarate, an intermediate of the tricarboxylic acid (TCA) cycle

      • VGluTs – package Glutamate into SVs

      • EAATS – excitatory amino acid transporters

        • Remove glutamate from synaptic cleft

  • Glutamate Removal 

    • the action of glutamate released into the synaptic cleft is terminated by uptake into neurons and surrounding glial cells via specific transporters. 

      • EAATS

    • Important to protect against excitotoxicity 

      • Red = membrane transporter 

      • Blue = vesicular transporter

  • Glutamate: neuropharmacology 

    • Diseases glutamate implicated in

      • Excitotoxicity (excessive stimulation of neurotransmitters kills neurons) has been implicated as a mechanism of neuronal death in acute and chronic neurologic diseases

        • Cerebral ischemia

        • traumatic brain injury (TBI)

        • prolonged seizure activity

        • ALS

          • excitotoxicity

        • Alzheimers

          • Excitotoxicity

    • Drugs that influence Glutamate 

      • Memantine (Namenda)

        • NMDA receptor antagonist

        • mitigates excitotoxicity and slows down Alzheimer's symptoms



  • GABA

    • γ-Aminobutyric acid 

    • Although chemically it is an amino acid, it is not an alpha amino acid, and is never incorporated into a protein.

    • chief inhibitory neurotransmitter in the mammalian CNS

      • binding causes the opening of ion channels to allow the flow of either Cl- ions into the cell or K+ out of the cell. 

      • causes a negative change in the transmembrane potential, usually causing hyperpolarization.

      • ~1/3 of CNS synapses use GABA

    • Regulates neuronal excitability

    • also directly responsible for the regulation of muscle tone

  • GABA synthesis

    • Synthesized from glutamate (therefore glucose primary precursor)

    • Vesicular GABA transporters are the vGATS

    • GAD – glutamic acid decarboxylase

      • Exclusively in GABAergic neurons

      • Requires pyridoxal phosphate for activity

        • Derived from VitaminB6

        • Thus B6 deficiency can lead to ↓ GABA synthesis

    • Removal by transporters, GATs

      • In terminals and glia

      • Degradative enzymes are in mitochondria

  • GABA: neuropharmacology 

    • Disease GABA implicated in 

      • Epilepsy 

      • Infant seizures

        • Vitamin B6 deficiency can impair GABA synthesis

      • Huntington's

      • Parkinson's

      • Dementia

      • Alzheimer's

      • Schizophrenia

    • Drugs that influence GABA

      • Valproic acid

        • Anticonvulsant

        • Inhibits GABA transminase

      • Barbiturates

        • Agonists or modulators of GABA receptors

        • Used to treat epilepsy

      • γ-hyydroxybuturate 

        • GABA Derivative (CNS depressant)

        • Date rape drug (also called cherry meth, liquid X, fantasy, organic quaalude, GBH, salty water, Georgia home boy, scoop, sleep-500, soap, liquid E, somatomaz, liquid ecstasy, and
          vita-G.

        • Euphoria, memory deficits, unconsciousness

        • Treatment for narcolepsy

      • Increase GABA to terminate seizures

        • Seizures facilitated by lack of neuronal inhibition

    • GABA is a major source of the drugs used to treat various things

  • Biogenic amines 

    • regulate many CNS functions

      • Homeostasis to attention

    • Also active in PNS

    • Defects implicated in most psychiatric disorders

      • Pharmacology of the amine synapse critically important for psychotherapy

      • Drugs affecting synthesis, receptor binding or catabolism amongst the most important in modern pharmacology

    • 5 well established biogenic amine neurotransmitters

      • Catecholamines (synthesized from Tyrosine)

        • Domapine

        • Norepinephrine (noradrenaline)

        • Ephinephrine (adrenaline)

      • Indolamines (synthesized from Tryptophan)

        • Serotonin

        • Histamine

  • Catecholamines in CNS

    • Widespread projections…not that many neurons

  • Catecholamine Synthesis 

    • Biogenic amines regulate many CNS functions

      • Homeostasis to attention

    • Also active in PNS

    • Defects implicated in most psychiatric disorders

    • Which enzymes you traffic to the terminal determines how far donw the pathway you go 

  • Dopamine 

    • a simple organic chemical in the catecholamine family

    • As a chemical messenger, dopamine is similar to adrenaline. 

    • plays a major role in the brain system that is responsible for reward-driven learning

      • a variety of highly addictive drugs, including stimulants such as cocaine and methamphetamine, act directly on the dopamine system.

    • affects brain processes that control movement, emotional response, and ability to experience pleasure and pain. 

    • people with extraverted (reward-seeking) personality types tend to show higher levels of dopamine activity than people with introverted personalities

  • Dopamine syntheiss 

    • Produced by conversion of 

      • 1. tyrosine to DOPA by TH, 

      • 2. DOPA to dopamine by Dopa-decarboxylase

    • Vesicular DA transporters are the vesicular monoamine transporters (vMATs)

      • vMAT1 and vMAT2

      • Load all monoamine transporters into SVs

    • 2 major enzymes involved in catabolism of DA

      • MAO (mitochondria)

      • COMT (cytoplasm)

    • Neurons contain both MAO and COMT

    • Reuptake by transporters in terminals

      • DAT (Dopamine transporter)

        • Na +/Cl − -dependent reuptake of extracellular dopamine (DA)

      • Can also be removed by NET (Norepinephrine transporter)

    • Remaining DA diffuse to circulatory system and destroyed in liver

    • Tyrosine

      • Amino acid used in protein synthesis

      • Can  be synthesized in the body from phenylalanine

      • Dietary sources. Found in many high-protein food products

  • Dopamine: neuropharmacology

    • Diseases DA implicated in 

      • Parkinsons

        • DA+ neurons degenerate in Substantia nigra

      • Addiction

        • Opioid and cannabinoid transmission instead of dopamine may modulate consummatory pleasure and food palatability

    • Drugs that influence DA

      • Neuroleptics (antipsychotics)

        • reduce dopamine activity

          • impair concentration

          • reduce motivation

          • cause anhedonia

      • Levodopa

        • Dopamine precursor

        • Used to treat Parkinson's disease and dopa-responsive dystonia

      • Carbidope (Sinemet)

        • Inhibitor of dopa-decarboxylase

        • Used to treat epilepsy

  • Norepinephrine (noradrenaline)

    • multiple roles including as a hormone and a neurotransmitter

    • PNS: Released from sympathetic neurons

    • CNS: in neurons of  locus coeruleus (brain stem)

      • Influences sleep and wakefulness, attention, feeding

    • Acts as a stress hormone, 

      • Affects amygdala, where attention and responses are controlled

  • Norepinephrine synthesis  

    • 1. Tyrosine (Tyr) is converted to DOPA by tyrosine hydroxylase (rate-limiting step for NE synthesis).

    • 2. DOPA is converted to dopamine (DA) by DOPA decarboxylase.

    • 3. Dopamine is transported into vesicles then converted to norepinephrine (NE) by dopamine β-hydroxylase (DBH)

      • transport into the vesicle can by blocked by the drug reserpine.

    • 4. When NE released DBH is released along with the NE.

    • 5. Removed via Norepinephrine transporter (NET) transporters

      • 1. In terminals

      • 2. Can also remove dopamine

  • Epinephrine (adrenaline)

    • a hormone and a neurotransmitter

    • PNS: increases heart rate, constricts blood vessels, dilates air passages and participates in the fight-or-flight response of the sympathetic nervous system

    • CNS

      • lower levels and fewer neurons than other catecholamines

      • Primarily in lateral tegmental system  and medulla (brainstem)

      • Function unknown

    • Also made in adrenal medulla

      • Release controlled by sympathetic nervous system

  • Epinephrine synthesis

    • PNMT only found in epinephrin-secreting neurons

    • Loaded into SVs by transporter, VMAT

    • have not identified specific transporter yet

      • NET capable of uptake

    • Extra enzymes…can’t be a dopaminergic neuron…will turn to norepinephrine….

  • Metabolism

    • NE and epinephrine are metabolized by catechol-O-methytransferase (COMT) and monoamine oxidase (MAO). 

    • The final product of these pathways is vanillylmandelic acid (VMA).


  • Histamine and Serotonin in CNS

  • Serotonin

    • 5-hydroxytryptamine (5-HT) 

    • a monoamine neurotransmitter

    • in humans, serotonin levels are affected by diet. 

      • An increase in the ratio of tryptophan to phenylalanine and leucine will increase serotonin levels. 

    • Involved in regulation of mood, appetite, and sleep. 

    • has some cognitive functions, including memory and learning. 

    • Modulation of serotonin at synapses is thought to be a major action of several classes of pharmacological antidepressants.

    • thought to be a contributor to feelings of well-being and happiness

    • Found in gastrointestinal (GI) tract, platelets, and CNS

    • CNS: primarily in neurons of Raphe nucleus and PONS and upper brainstem

  • Serotonin synthesis 

    • Biochemically derived from tryptophan

      • Amino acid used in protein synthesis

      • Essential amino acid

    • Dietary sources

      • routine constituent of most protein-based foods or dietary proteins

      • When food is ingested that contains tryptophan, the molecule is extracted during metabolic processes that take place in the small intestine, and absorbed into circulation. 

      • There, it travels through the body, crosses the blood–brain barrier, and enters neurons, where it gets metabolized into indolamine neurotransmitters (classification of monoamine neurotransmitters including serotonin and melatonin), as well as niacin. 

  • Serotonin synthesis and reuptake 

    • Loaded into SVs by vMAT

    • Reuptake by SERT

      • Present in terminals

  • Metabolism 

    • Serotonin is degraded in two reactions 

  • 5HT: neuropharmacology 

    • Diseases 5HT implicated in 

      • Depression 

      • Migraine

    • Drugsst ath influence 

      • SSRIs (e.g. Prozac)

        • Inhibit 5HT uptake in presynaptic terminals

          • Increase extracellular levels

      • Sumatriptan (Imatrex)

        • 5HT receptor agonist

        • Vasoconstrictor of intracranial arteries

        • Used to treat migraine

  • NT Transporters 

      • EAATS – excitatory amino acid transporters

  • Transporters and Co-transmissions 

    • DO NOT NEED TO KNOW FOR THE TEST

  • Purinergic transmission 

    • The purines are another group of small molecule transmitters

      • adenosine triphosphate (ATP)

      • adenosine

    • Excitatory in both CNS and PNS

    • Released with other neurotransmitters 

      • co-transmitters

    • Act principally as neuromodulators but can be primary mediators

  • Neuromodulator vs Neurotransmitters

    • Neurotransmitter 

      • a messenger released from a neuron at an anatomically specialized junction, which diffuses across a narrow cleft to affect one or sometimes two postsynaptic neurons, a muscle cell, or another effector cell. 

    • Neuromodulator 

      • a messenger released from a neuron in the central nervous system, or in the periphery, that affects groups of neurons, or effector cells that have the appropriate receptors. 

      • It may not be released at synaptic sites, it often acts through second messengers and can produce long-lasting effects. 

      • The release may be local so that only nearby neurons or effectors are influenced, or may be more widespread, which means that the distinction with a neurohormone can become very blurred

    • Neurohormone 

      • a messenger that is released by neurons into the extracellular fluid/blood and which may therefore exert its effects on distant peripheral targets. 

      • It may differ only in degree from a neuromodulator in the extent of its action

  • Gaseous transmitters

    • Fairly newly recognized class of neurotransmitters. Include 

      • Nitric oxide (NO) 

      • carbon monoxide (CO)

    • Do not satisfy some of the criteria formulated for classic neurotransmitters

      • Not stored in vesicles (made when needed)

      • Not released by Ca2+-dependent exocytosis from a presynaptic terminal

      • Inactivation is passive (no active process to terminate action)

      • Do not act on receptors on target cells

        • Not confined to a pre- to post-synaptic direction

        • Depends on diffusion

      • Acts as retrograde messengers

        • Regulates function of axon terminals presynaptic to the neuron in which it was made

  • Nitric oxide (NO)

    • a gas produced by nitric oxide synthase (NOS)

    • NOS is an enzyme that converts arginine to citrulline, thereby releasing NO

    • Can be considered a second messenger, rather than a neurotransmitter

      • Activates guanylyl cyclase to produce cGMP

    • NO can permeate plasma membrane (lipid soluble)

      • therefore can influence nearby cells

      • Can diffuse a few 10s of µm from its site of production before degradation

      • Can coordinates activities of small network of neurons

      • Decays spontaneously by reacting with oxygen to produce inactive nitrogen oxides

      • NO signal only lasts a short time (seconds or less)

    • Regulates a variety of synapses which also employ conventional neurotransmitters

      • Presynaptic glutamatergic terminals best studied target for NO in CNS

    • * Able to signal back to another cell 

  • Carbon monoxide (CO)

    • a neuronal form of heme oxygenase occurs in discrete neuronal populations in the CNS

    • CO formed from it may be involved in regulating levels of cyclic GMP

    • Also formed in cytolplasm

    • Rapidly diffuses through membrane and can effect local cells to stimulate productions on second messengers

    • Broken down rapidly (only exist for a few seconds)

      • Difficult to study!!

  • Endocannabinoids 

    • a family of lipid molecules that act as key regulators of synaptic transmission and plasticity

    • are synthetized “on demand” following physiological and/or pathological stimuli

    • Canonical mechanism of action

      • Once released from postsynaptic neurons, eCBs typically act as retrograde messengers to activate presynaptic type 1 cannabinoid receptors (CB1) and induce short- or long-term depression of neurotransmitter release

    • Recent findings have revealed a number of less conventional mechanisms by which eCBs regulate neural activity and synaptic function, suggesting that eCB-mediated plasticity is mechanistically more diverse than anticipated.

      • mechanisms include non-retrograde signaling, signaling via astrocytes, participation in long-term potentiation, and the involvement of mitochondrial CB1.